These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2008-001804-22 A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of sy... bad-data
Listed as ongoing, but also has a completion date 2008-001805-40 A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (le... 2010-08-27 bad-data
Not reported 2010-018999-25 A Phase III, multicentre, clinical study investigating the efficacy and safety of 3-months open-label treatment with PGL4001, followed by a randomised, double-blind placebo controlled period of 10 day... 2012-02-02 due-trials
Listed as ongoing, but also has a completion date 2010-019497-32 A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatment ... 2013-02-27 bad-data
Listed as ongoing, but also has a completion date 2011-005167-24 A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo controlled Study of the Steroid Sulfatase Inhibitor PGL2001 with concomitant administration of NETA (norethisterone ... 2014-02-28 bad-data
Listed as ongoing, but also has a completion date 2012-000036-26 A Phase III, multicentre, randomized, double-blind clinical study, investigating the efficacy and safety of repeated 12-week courses of daily 5mg or 10mg doses of PGL4001 for the long-term management ... 2015-01-19 bad-data
Not reported 2012-001219-22 A Phase IIa study investigating the efficacy and safety of the c-Jun-N-Terminal Kinase (JNK) inhibitor PGL5001 versus placebo administered for up to 5 months with concomitant administration of depot m... 2014-05-06 due-trials
Listed as ongoing, but also has a completion date 2012-001465-33 A Phase III, multicentre, extension study investigating the 2015-04-19 bad-data